Aptevo Therapeutics Doses First Patient in Phase 1/1b Clinical Trial of Lead Next-Generation Bispecific Antibody APVO436
December 13, 2018 09:02 ET
|
Aptevo Therapeutics Inc.
Preclinical Data for APVO436 Show Potential Best-in-Class Attributes with Potent T-Cell Directed Tumor Killing and Reduced Cytokine Production Compared to a Competitor Construct Phase 1/1b Clinical...
Aptevo Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
November 20, 2018 09:00 ET
|
Aptevo Therapeutics Inc.
SEATTLE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that...
Aptevo Therapeutics Reports Third Quarter 2018 Financial Results
November 14, 2018 16:02 ET
|
Aptevo Therapeutics Inc.
Achieves 132% Increase in IXINITY® Quarterly Net Revenue Year-Over-Year More than Doubles Year-to-Date IXINITY Net Revenue from $8.1 Million to $16.7 Million Advances Bispecifics APVO436...
Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting
November 09, 2018 00:00 ET
|
Aptevo Therapeutics Inc.
Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses Targets 5T4 Cancer Antigen Present on Many Types of Solid Tumors LUND,...
Aptevo Therapeutics Announces Expanded Growth Initiatives for IXINITY
October 24, 2018 09:00 ET
|
Aptevo Therapeutics Inc.
Plans to Introduce 3000 IU IXINITY Assay for Enhanced Patient Convenience Will Commence Pediatric Study Seeking U.S. Label Expansion Explores Ex-US Licensing and Partnership Collaborations to Expand...
Aptevo Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference
September 25, 2018 11:29 ET
|
Aptevo Therapeutics Inc.
SEATTLE, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that...
Aptevo Therapeutics Reports Second Quarter 2018 Financial Results
August 09, 2018 09:00 ET
|
Aptevo Therapeutics Inc.
Achieves Record IXINITY® Net Revenue with 94% Increase inYear-Over-Year Quarterly Revenue Publishes and Presents New Data on Multiple ADAPTIR™ Bispecific CandidatesShowing Robust Immune System...
Aptevo Therapeutics Revises Term Loan Agreement With MidCap Financial; Reduces Cash Requirements by $18 Million
August 07, 2018 09:00 ET
|
Aptevo Therapeutics Inc.
Defers Principal Repayments to February 2020 and Reduces Restricted Cash Covenant Aptevo to Announce Second Quarter 2018 Financial Results on August 9, 2018 SEATTLE, Aug. 07, 2018 (GLOBE NEWSWIRE)...
Novel First-In-Class Immunotherapeutic APVO210 Features Unique Mechanism of Action Delivering IL-10
May 29, 2018 09:00 ET
|
Aptevo Therapeutics Inc.
Suppresses Inflammation and Immune Activation Without Lymphocyte Stimulation New Preclinical Data Published in ‘Frontiers in Immunology’ Show APVO210 Holds Promise in the Treatment of Autoimmune...
Aptevo Therapeutics Reports First Quarter 2018 Financial Results
May 10, 2018 09:00 ET
|
Aptevo Therapeutics Inc.
Almost Doubles Year-Over-Year IXINITY Quarterly Revenue Files IND for APVO436 and Advances APVO210 Toward a Planned Q4 2018 IND Submission Presents Data at AACR Annual Meeting Showing...